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Abstract
Introduction: Early detection of dementia symptoms is critical in Down syndrome
(DS) but complicated by clinical assessment barriers. The current study aimed to char-
acterize cognitive andbehavioral impairmentusing longitudinal trajectories comparing
several measures of cognitive and behavioral functioning.
Methods: Measures included global cognitive status (Severe Impairment Battery
[SIB]), motor praxis (Brief Praxis Test [BPT]), and clinical dementia informant ratings
(Dementia Questionnaire for People with Learning Disabilities [DLD]). One-year reli-
ability was assessed using a two-way mixed effect, consistency, single measurement
intraclass correlation among non-demented participants. Longitudinal assessment of
SIB, BPT, and DLDwas completed using linear mixed effect models.
Results: One-year reliability (n = 52; 21 male) was moderate for DLD (0.69 to 0.75)
and good for SIB (0.87) and BPT (0.80). Longitudinal analysis (n = 72) revealed signif-
icant age by diagnosis interactions for SIB (F(2, 115.02) = 6.06, P = .003), BPT (F(2,
85.59)= 4.56, P= .013), and DLD (F(2, 103.56)= 4.48, P= .014). SIB progression (PR)
had a faster decline in performance versus no-dementia (ND) (t(159) = −2.87; P =
.013). Dementia had a faster decline in BPT performance versus ND (t(112) = −2.46;
P = .041). PR showed quickly progressing scores compared to ND (t(128) = −2.86;
P= .014).
Discussion: Current measures demonstrated moderate to good reliability. Longitudi-
nal analysis revealed that SIB, BPT, andDLDchangedwith age depending on diagnostic
progression; no change rates were dependent on baseline cognition, indicating useful-
ness across a variety of severity levels in DS.
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1 INTRODUCTION
There is a clear connection between dementia, especially Alzheimer’s
disease (AD), and aging in people with Down syndrome (DS). Almost all
individuals with DS from their mid-30s on have neuropathology con-
sistent with AD including amyloid plaques and neurofibrillary tangles.1
Notably, pathological changes have been documented in individuals
with DS as young as 20 years of age, or ≈50 years earlier than in
neurotypical aging groups.2–4 This acceleration of pathology is likely
related to the location of the APP gene and other overexpressed genes
on chromosome 21, which is triplicated in individuals with DS.1,5–7 In
addition to triplicated APP, individuals with DS have additional AD risk
factors including oxidative damage, neuroinflammation, higher rates of
apolipoprotein E ε-4 allele (APOE ε4/ε4, ε4/ε3, ε4/ε2), propensity for
sleep apnea, and premorbid intellectual disabilities.1,5,8,9
Improved medical care has resulted in an increased mean life
expectancy for individualswithDS to age53,withmore than70% living
past the age of 30 years and 20% living past 55 years.5,10,11 Together
with increased lifespan, the factors above contribute to greaterAD risk
in adults with DS than in other populations with intellectual disabili-
ties or the general population.12 Between the ages of 30 and 39≈3.4%
of individuals withDS are diagnosedwith dementia; however, research
suggests that vulnerability to atypical aging begins around age 35,2,13
and dementia prevalence increases to 40%between the ages of 50 and
59.14,15 Given the exponential increase in AD-related neuropathology
and dementia diagnosis, it is essential to detect early pathological and
cognitive AD changes to enhance clinical intervention and long-term
care for individuals with concurrent DS and dementia.
1.1 Detection of incipient AD in DS
With enhanced technology and understanding of disease progres-
sion, research has increasingly focused on detection of early cogni-
tive and behavioral changes. Notably, individuals with DS and prodro-
mal AD demonstrate early behavioral changes that appear comparable
to those of neurotypical adults with mild cognitive impairment (MCI).
Specifically, behavioral changes such as delusions andviolent outbursts
(either physical or verbal) appear more prevalent in adults with DS
early in dementia while nighttime confusion, agitation, wandering, and
visual hallucinations aremore prominent in later stages.16 Such behav-
ioral changes are generally accessible and easily studied in individuals
with DS given availability of informant ratings.
Unfortunately, the onset and course of cognitive changes in individ-
uals with DS and AD remains less clear. Early detection of cognitive
changes in individuals with DS is complicated by the inherent difficulty
of assessing cognition in the context of moderate to severe intellectual
disability (ID). Additional assessment difficulties within this popula-
tion include large intra- and inter-individual variability in cognition and
behavior, differential diagnosticmethods, identification of an appropri-
ate baseline, selection of ameaningful control group, and tolerability of
the testing process. Despite recent reports (Firth et al.17), a “gold stan-
dard” neurocognitive battery has not been established, especially as
RESEARCH INCONTEXT
1. Systematic review: Early detection of dementia is com-
plicated by inherent clinical assessment barriers for indi-
viduals with Down syndrome (DS) including intellectual
disability (ID), large intra- and inter-individual variability,
identification of appropriate baseline levels of function-
ing, selection of tests with appropriate cut scores, and
patient tolerability of testing. The current study aimed
to characterize the degree of cognitive and behavioral
impairment using longitudinal cognitive trajectories com-
paring several measures of cognitive and behavioral func-
tioning.
2. Interpretation: Measures of global cognitive status,
motor praxis, and clinical dementia informant ratings
demonstrated moderate to good 1 year reliability. Lon-
gitudinal analysis revealed that these measures changed
with age depending on diagnostic progression and were
not dependent on baseline level of ID, indicating their
usefulness across a variety of ID levels in DS.
3. Future Directions: Future research should compare the
current cognitive measures to biomarkers including neu-
roimaging, blood biomarkers, and other physiological
indicators of neurodegeneration in a longitudinal fashion
to further validate and enhance sensitivity to dementia-
related cognitive changes in DS.
measures used for diagnosingMCI and dementia in typical aging adults
are often inappropriate for use in DS populations given pre-existing
ID.18 Moreover, few measures have established cut scores for use in
DS.19
1.2 Utility of cognitive measures
Recent efforts within the field have focused on determining the util-
ity of cognitive measures in detecting prodromal dementia and AD in
adults with DS. For instance, Walsh et al.20 examined cognitive mark-
ers in 114 individuals with DS, 62% of whom carried dementia diag-
noses, in an attempt to validate the Rapid Assessment of Developmen-
tal Disabilities (RADD) for use in dementia diagnostics. RADD scores
were compared to performances on the Brief Praxis Test (BPT), Severe
ImpairmentBattery (SIB), andDementia Scale for Peoplewith Learning
Disabilities (DLD). Results indicated strong correlations between the
RADDand BPT (r= 0.842), SIB total (r= 0.921), andDLD sumof cogni-
tive subscale scores (r= 0.889) indicating strong content concordance
betweenmeasures.20
Further research on the SIB indicates a strong association in SIB
total scores between persons with AD in the general population and
those with concurrent DS and dementia once adjusted for sex and
KOEHL ET AL. 3 of 8
functional impairment.21 Both the SIB and DLD have longstanding
established reliability and validity,22,23 with such evidence supporting
the appropriateness of using the SIB as a domain-based, yet brief,
assessment of cognitive change in DS.
1.3 Longitudinal assessment
Few studies have tracked longitudinal cohorts in an attempt tomonitor
cognitive changes and address the utility of specific cognitivemeasures
including the SIB, BPT, and DLD. In one such study, McCarron et al.24
followed 77 women with DS over a 14-year period with annual vis-
its. Notably, the DLD appeared particularly sensitive to early and pro-
gressive cognitive change over time; this was in direct contrast to the
DownSyndromeMental Status Examination (DSMSE),which appeared
less sensitive and best suited for those with less severe levels of ID.24
Despite the availability of only limited longitudinal data, researchers
and clinicians alikeunderstand the importanceof early and regular cog-
nitive screening. Clinically, longitudinal measurement has gained trac-
tion as a means of early AD detection, beginning with a baseline evalu-
ation at age 35 and with follow-ups annually or as needed.25 However,
to the authors’ knowledge, no studies to date have empirically exam-
ined the longitudinal trajectories and clinical utility of the BPT, SIB, and
DLD in a diverse cohort of individuals with DS.
The Aging in Down Syndrome Study (ADS) at the University of Ken-
tucky currently follows one such unique cohort. The present analyses
examined longitudinal cognitive and behavioral symptoms from base-
line through conversion to and progression of AD using the BPT, SIB,
andDLD. Several models were tested includingwhether rate of change
was dependent on time, age, baseline ID level, and diagnosis for each
of these measures. It was hypothesized that rate of change on all mea-
sures would be greater with time accrual and increased age at base-
line diagnosis. While lower ID baselines were hypothesized to be asso-
ciatedwith initially lower baseline scores, rate of change over timewas
hypothesized to be independent of ID status.
2 METHODS
2.1 Participants
Research procedures were approved by the University of Kentucky
Institutional Review Board. Participants completed approved proto-
cols for informed consent or assent with guardian approval. Partici-
pants were community residing men and women with DS recruited
through local DS support groups and residential facilities primarily in
Kentucky, southern Indiana, and southernOhio.
Participants were included in the test–retest reliability analysis if
they had a neuropsychological evaluation and were stable with no
dementia at both years. Therewere 52 participantswhowere included
in the analysis. For the longitudinal analysis 95 participants had more
than one visit. Participants were excluded (n = 23) from the longitudi-
nal analysis if they had other ongoing medical conditions or environ-
mental changes that made consensus diagnosis undeterminable. Thus,
72 participants were included in the longitudinal analysis.
2.2 Assessments
Clinical assessments included the BPT, SIB, and DLD. The BPT26 is a
measure of dyspraxia that is amodification of the original 62-itemDys-
praxia Scale for Adults with Down Syndrome. The BPT consists of 20
items selected from the original for maximum change demonstrated
over 3 years.27 The BPT requires minimal verbal demands and instead
uses simple behavioral output. Low scores on the BPT indicate severe
dyspraxia. The SIB28 was developed to assess cognition in severely
impaired individuals. By using one-step commands and gestural cues,
the SIB allows for non-verbal responses andpartially correct responses
to assess behavioral and cognitive symptoms in individuals with severe
dementia. The SIB yields a total score along with six major subscales
including attention, orientation, language, memory, visuospatial abil-
ity, and construction; lower scores indicate more severe deficits. The
DLD22 is a diagnostic screening tool thatmeasures behavioral and cog-
nitive dysfunction as reported by caregivers or guardians. It consists
of 50 items resulting in a sum of cognitive scores including: short-term
memory, long-term memory, and spatial/temporal orientation along
with a sum of social scores including speech, practical skills, mood,
activity/interest, andbehavioral disturbance.Higher scoreson theDLD
indicate more severe deterioration. DLD raters for the current study
were caregivers and/or legal guardians who were responsible for daily
care of the participants either in the home or an assisted living setting.
2.3 Consensus diagnosis
Dementia diagnoses were determined through an expert diagnostic
consensus review consisting of one neuropsychologist, one psycholo-
gist, and three neurologists and are based on NINCDS-ADRDA crite-
ria. Baseline levels of ID were determined by caregiver report of prior
evaluation results and by review of records when available.
2.4 Statistical analysis
A two-way mixed effect, consistency, single measurement intraclass
correlation (ICC[3,1]) was calculated for the SIB, BPT, and DLD. The
objective was to quantify the reliability of primary cognitive and
dementia outcome scales over a 1-year period among non-demented
(ND) individuals with DS. Reliability was considered poor if the ICC
was <0.5, moderate if ICC was between 0.5 and 0.75, good if the ICC
was between 0.75 and 0.9, and excellent if ICC was >0.90.29 All anal-
yses were completed using R 3.6.130 and the “irr” package.31 Reliable
change indices were calculated using the methods described by Jacob-
son and Truax32 along with Chelune et al.33 These indices reflect the
amount of change in each assessment needed to be 90% or 95% confi-
dent the change is beyond normal variability.
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TABLE 1 Participant characteristics for test–retest reliability
Year 1 and 2 (N= 52)
% (n) Mean (SD) Median [Q1–Q3]
Sex
Male 40.38% (21)
Female 59.62% (31)
ID level
Borderline 3.85% (2)
Mild 55.77% (29)
Moderate 38.46% (20)
Profound 0% (0)
Severe 0% (0)
Not documented 1.92% (1)
Age 38.96 (9.28) 37.06 [32.66–44.75]
Time (years) 1.02 (0.10) 1.02 [0.98–1.05]
SIB total 82.21 (15.92) 87 [73.50–94]
BPT total 69.60 (8.79) 72 [64.50–76]
DLD total 9.77 (8.38) 7 [3–14.5]
DLD cognitive 4.44 (5.64) 2 [0–6]
DLD social 5.33 (4.25) 5 [2–8]
Abbreviations: BPT, Brief Praxis Test; DLD, Dementia Questionnaire for
People with Learning Disabilities; ID, intellectual disability; SD, standard
deviation; SIB, Severe Impairment Battery.
Longitudinal analysis of SIB, BPT, and DLD was completed using
mixed effectsmodels. The objective of this analysis was to evaluate the
rate of change in the SIB, BPT, and DLD across ages for participants
who remained ND versus those who progressed to dementia (PR), ver-
sus thosewho had dementia as baseline (DM). First, the randomeffects
were specified using the restricted likelihood method. Random inter-
cept versus random intercept and slope models were compared. The
random interceptmodelwas selected as therewere no issueswith con-
vergence. Then main effects and interactions of the fixed effects (eg,
age and disease progression) were fitted using themaximum likelihood
method. Post-hoc comparisons used the Tukey correction for multiple
comparisons. Model fit was selected based on loglikelihood of nested
models, Akaike information criterion (AIC), and Bayesian information
criterion (BIC). All analyses were completed using R 3.6.130 and the
“lme4”34 and “lmerTest”35 packages.
3 RESULTS
3.1 Test–retest reliability
Between years 1 and 2 therewere 52 eligible participantswho had SIB,
BPT, or DLD data. Of these 49 participants, 42 to 43 participants had
data for each specific test. Full participant characteristics are included
in Table 1. Results of the reliability analyses are reported in Table 2. SIB
and BPT test–retest reliability over the first year of assessment was
good. DLD total score and subscore reliability wasmoderate. DLD cog-
nitive subscore reliability had slightly better reliability than DLD social
subscore (Table 2). Reliable changes indices revealed that over the first
year, a decrease of 12 points on the SIB and of 10 points on the BPT
were associated with 90% confidence that a real change occurred. On
the DLD, increases of 11 points in the total score, 7 points in the cog-
nitive subscore, and 6 points in the social subscore were associated
with90%confidenceof real change.More conservative reliable change
indices (at 95% confidence) are provided in Table 2.
3.2 Longitudinal analysis
Therewere 72 participants (n= 32male) whowere eligible for the lon-
gitudinal analysis. About 64% of participants had four or fewer follow-
up visits, the remainder having five or more, for an average number of
4.35 visits and follow-up time of 3.53 years. Full participant character-
istics are provided in Table 3.
3.2.1 Brief praxis test
Age (F(1,94.51) = 10.03; P = .002), ID level (F(1,60.10) = 7.35; P =
.009), and diagnosis progression (F(2, 70.26) = 11.33; P < .001) were
all found to be significantly associated with BPT total score. Sex was
not significantly associatedwithBPT total score andwas dropped from
the model. For each year increase in age, BPT scores dropped 0.40
points (t(94.51) = −3.17; P = .002). Individuals with moderate to pro-
found ID scored 5.79 points lower than those with borderline/mild ID
(t(60.10) = −2.71; P = .009). Using a Tukey correction for multiple
comparisons, individuals with DM had significantly lower BPT scores
than the ND (difference = −12.36; t(93.50) = −3.32; P = .004) or
TABLE 2 Summary of test–retest reliability and reliable change indices
n Time 1mean (SD) Time 2mean (SD) ICC (95%CI) 90%RCI 95%RCI
SIB 43 84.16 (15.00) 86.37 (11.75) 0.87 (0.77–0.93) 12 14
BPT 42 70.57 (9.09) 70.98 (8.71) 0.80 (0.66–0.89) 10 11
DLD 43 8.98 (8.09) 9.19 (8.38) 0.71 (0.53–0.83) 11 13
DLD –Cognitive 43 3.86 (5.19) 4.33 (6.19) 0.75 (0.58–0.86) 7 8
DLD – Social 43 5.12 (4.44) 4.86 (4.09) 0.69 (0.49–0.82) 6 7
Note: RCI values were rounded up to next whole number.
Abbreviations: BPT, Brief Praxis Test; DLD; ICC, intraclass correlation; RCI, reliable change index; SD, standard deviation; SIB, Severe Impairment Battery.
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TABLE 3 Participant characteristics for longitudinal analysis
% (n) Mean (SD) Median [Q1–Q3]
Sex
Male 44.44% (32)
Female 55.56% (40)
ID level
Borderline/mild 48.61% (36)
Moderate to
profound
47.22% (34)
Not documented 1.39% (1)
Baseline diagnosis
No dementia 72.22% (52)
Possible dementia 9.72% (7)
Probable dementia 18.06% (13)
Last diagnosis
No dementia 56.94% (41)
Possible dementia 9.72% (7)
Probable dementia 33.33% (24)
Diagnosis progression
Remained
non-Demented
53.94% (41)
Progressed 23.61% (17)
Dementia at
baseline
19.44% (14)
Follow-up (years) 3.53 (2.28) 2.91 [1.93–5.38]
Age 41.31 (10.57) 39.50 [33–50]
SIB total 79.64 (19.06) 87 [70–93]
BPT total 67.80 (11.71) 71.50 [63–76]
DLD total 15.10 (13.59) 11 [4–21]
DLD cognitive 7.52 (8.72) 4 [1–14]
DLD social 7.58 (6.10) 6 [3–11]
Abbreviations: BPT, Brief Praxis Test; DLD, Dementia Questionnaire for
People with Learning Disabilities; ID, intellectual disability; SD, standard
deviation; SIB, Severe Impairment Battery.
PR (difference = −15.74; t(83.00) = −4.54; P < .001) cohorts.
There was no significant difference between the ND and PR groups
(P> .05).
Next, a model examining the interaction of age and diagnosis pro-
gression was examined. The interaction model provided better fit than
the main effects model based on AIC and likelihood ratio test. BIC was
not smaller in the interaction compared to themain effectmodel. Thus,
the change in BPT scores across age depended on diagnosis progres-
sion status (F(2, 85.59) = 4.56; P = .013). Using a Tukey correction for
multiple comparisons, the DM group had a significantly faster decline
in BPT performance compared to the ND cohort (t(112) = −2.46; P
= .041), but the PR group did not (t(112) = −2.03; P = .109). There
was no significant difference between the DM and PR groups (P > .05;
Figure 1A).
3.2.2 Severe impairment battery
Age (F(1,127.77) = 6.77; P = .010), ID level (F(1,67.52) = 11.22; P =
.001), and diagnosis progression (F(2, 78.83) = 6.69; P = .002) were
all found to be significantly associated with SIB total score. Sex was
not significantly associated with SIB total score and was dropped from
the model. For each year increase in age, SIB scores dropped 0.48
points (t(127.77)=−2.60; P= .010). Individuals with moderate to pro-
found ID scored 11.30 points lower than thosewith borderline/mild ID
(t(67.53)=−3.35;P= .001). Using a Tukey correction formultiple com-
parisons, individuals with DM had significantly lower SIB scores than
the ND (difference = −18.06; t(97.50) = −3.19; P = .005) or PR (dif-
ference = −16.75; t(80.50) = −3.17; P = .006) cohorts. There was no
significant difference between the ND and PR groups (P> .05).
Next, a model examining the interaction of age and diagnosis pro-
gression was examined. The interaction model provided better fit than
the main effects model based on AIC, BIC, and likelihood ratio test.
Thus, the change in SIB scores across age depended on diagnosis pro-
gression status (F(2, 115.02) = 6.06; P = .003). Using a Tukey correc-
tion for multiple comparisons, the PR group had a significantly faster
decline in SIB performance compared to the ND cohort (t(159) =
−2.87; P = .013), but the DM group did not (t(118) = −2.35; P = .052).
There was no significant difference between the DM and PR groups
(P> .05; Figure 1B).
3.2.3 Dementia questionnaire for people with
learning disabilities
Age (F(1,110.03) = 4.56; P = .035) and diagnosis progression (F(2,
76.26) = 23.52; P < .001) were found to be significantly associated
with SIB total score. Sex and ID level were not significantly associated
with DLD total score and were dropped from the model. For each year
increase in age, DLD scores increased 0.33 points (t(110.03) = 2.14;
P = .035). Using a Tukey correction for multiple comparisons, individ-
uals with PR (difference= 11.00; t(82.00)= 2.87; P= .014) or DM (dif-
ference=29.60; t(90.30)=6.63;P< .001) had significantly higherDLD
scores thanND. Furthermore, thosewithDMhad elevatedDLD scores
compared to the PR group (difference = 18.50; t(76.00) = 4.53; P <
.001).
Next, a model examining the interaction of age and diagnosis pro-
gression was examined. The interaction model provided better fit than
the main effects model based on AIC and likelihood ratio test. BIC
was not smaller in the interaction compared to the main effect model.
Thus, the change in DLD scores across age depended on diagnosis pro-
gression status (F(2, 103.56) = 4.48; P = .014). Using a Tukey correc-
tion for multiple comparisons, the PR group had a significantly faster
increase in DLD score compared to theND cohort (t(128)=−2.86; P=
.014). There was no significant difference between the DM and PR or
ND groups (both P values > 0.05; Figure 1C). However, there was a
main effect of diagnosis progressionwhereby theDMgroup had signif-
icantly higher DLD total scores than ND (difference= 31.08; t(103.00)
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F IGURE 1 Predicted changes in primary outcomemeasures by age and progression status. A) BPT total score declinedwith increasing age at a
greater rate among those who had dementia from baseline (DM) compared to those who remained non-demented (ND); B) SIB total score declined
with increasing age at a greater rate among those who progressed (PR) compared to those who remained non-demented (ND); C) There were no
significant differences in rates of DLD change between groups, but there was amain effect of groupwhereby the DMgroup had significantly
higher DLD total scores than the ND and PR groups
=5.59;P< .001) andPR (difference=22.41; t(101.20)=3.69;P= .001)
groups (Figure 1C).
4 DISCUSSION
This study sought to characterize and compare over time the cog-
nitive trajectories of individuals with DS who remain non-demented,
those who progress to dementia, and those monitored after a
dementia diagnosis. The approach was two-fold: (1) to estimate
test–retest reliability of a short battery using the subsample of
individuals who remained non-demented over the course of the
1-year study period and (2) to estimate and compare rates of
change over time attributable to changes in clinical consensus
diagnosis.
Test-retest reliability estimates were acceptable for all three mea-
sures in the battery, with particularly good reliability for the SIB and
BPT. DLD test-retest reliability wasmoderate overall but was stronger
for the cognitive subscale than the social subscale. Themore objective,
task-oriented approach of SIB and BPT versus the more subjective,
caregiver-rating approach of the DLD may explain these reliability
differences across measures, whereas DLD subscale differences in
reliability potentially stem from the additional subjectivity involved in
rating social behavior versus cognitive ability within the DLD. Overall,
these estimates concord with prior studies and provide replication in
an independent sample.22,23,36
Moreover, the 90% confidence reliable change indexes computed
for use as a clinical tool to identify meaningful changes are nearly iden-
tical to previously suggested cutoff scores for the DLD and its sub-
scales, supporting those estimateswith a larger sample size and amore
extensive consensus process for group formation.22 Specifically, a 1-
year change in DLD Total Score of 11 points or more, in DLD Cognitive
scoreof6pointsormore, or inDLDSocial scoreof7pointsormore rep-
resented meaningful change with 90% confidence. Furthermore, the
current study adds to the DS literature by determining that a 1-year
change in SIB score of 12 points or more, or in BPT score of 11 points
ormore, reflect ameaningful changewith 90% confidence. These repli-
cated and novel change indices help provide context for what is and is
not ameaningful change.
Longitudinal changes in global mental status, praxis, and Clinical
Dementia Ratingwere generally in accordancewith previous literature
associating increased cognitive and functional impairment by various
measures, including theDLD, with passage of time, age at baseline, and
baseline level of ID.24 In the present study, BPT and SIB scores were
sensitive to baseline ID level, whereas DLD score was not. This may be
as expected for the DLD, which was designed explicitly to account for
developmental ID status, and for the SIB, which was not. More surpris-
ing is that the BPT was sensitive to baseline ID level despite its devel-
opment for use with individuals with DS. More crucially, the rate of
change on all three of our clinical measures was independent of base-
line ID status, demonstrating that longitudinalmonitoring does amelio-
rate the barrier that baseline ID presents tomeasurement of cognition
in the context of assessment for dementia. This time-dependent effect
demonstrates that theDLD, SIB, andBPTcandetect changes inDS indi-
viduals across a variety of ID levels and therefore could be useful in a
clinic setting.
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Individuals with dementia at study onset had, in general, a faster
decline than individuals who remained non-demented throughout.
However, trajectories for individuals who progressed from non-
demented to dementia during the study were not different from the
ND or DM groups despite trends to that effect (potentially due to
the small sample size of this group). These findings suggest a limited
utility of global mental status and praxis for early detection or pro-
dromal changes in contrast to much larger and complex cognitive
assessments (eg, Firth et al.17 and Startin et al.37). Ratings of clinical
dementia symptoms using the DLD showed equivalent, significant
decline for both the progression and dementia at baseline groups
compared to individuals who remained non-demented throughout
the observation period. This effect held for both the cognitive and the
social domains of the DLD. These longitudinal findings accord with and
extend prior reports of early social/behavioral changes prior to clinical
diagnosis of dementia.38 Moreover, results from the current study
indicate that perceived cognitive and social/behavioral changes may
appear on rating instruments such as the DLD before mental status
and praxis measures such as the SIB and BPT. This result supports a
previous longitudinal study of cognitive decline in DS, indicating that
informant ratings may better detect executive and cognitive function
declines.39
Mental status and praxis measures showed the expected perfor-
mance reductions across diagnostic categories, as well as the expected
decline over time in individuals with DS and comorbid dementia. They
were not, however, as sensitive to early changes of incipient dementia
as informant ratings. Relative sensitivity of the DLD to early changes
of incipient dementia compared to other measures may be due to a
number factors, including differences in instrument content, involve-
ment of caregivers in the assessment process, or difficulty motivating
and engaging individuals with DS and possible dementia in the formal
assessment process, as well as floor or ceiling effects on the objective
measures used.
The present study has several limitations. Wide inter-individual
variability in performance on clinical assessments, even within diag-
nostic status and ID level, limits detection of reliable effects and likely
makes the clinical recommendations for identifying reliable change
in individual scores overly conservative. Considerable intra-individual
variability in performanceon clinical assessments and in diagnostic sta-
tus over time poses similar problems and urges further caution regard-
ing generalizability of the present findings. Furthermore, due to the
recruitment limitations and high rate of loss to follow-up inherent in
studying this special population, sample sizes within diagnostic groups
are relatively small, andmost participants havebeenenrolled for a rela-
tively short time. Finally, data from the clinical batterywere included in
the overall consensus adjudication of diagnoses, presenting the threat
of criterion contamination endemic to clinical dementia research. The
present cohort enrolls continuously, and future sample growth and
follow-upwill mitigate themajority of these limitations. Ultimately, the
effect of criterion contamination will be addressed with additional val-
idation against neuropathology found at autopsy.
The current study revealed moderate to good reliability of assess-
ments for dementia in DS. Future prospective studies should evaluate
the predictive utility of reliable change indices. Furthermore, longitu-
dinal results revealed that the SIB, BPT, and DLD changed with age
depending on diagnosis progression across all levels of ID in DS. While
the SIB and BPT demonstrated that individuals who progressed to
dementia or were demented from baseline had faster rates of decline,
the DLD demonstrated the greatest separation in non-demented, pro-
gression, and demented cohorts.
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